Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Sci Signal
2011 Nov 01;4197:ra71. doi: 10.1126/scisignal.2001744.
Show Gene links
Show Anatomy links
p53 and microRNA-34 are suppressors of canonical Wnt signaling.
Kim NH
,
Kim HS
,
Kim NG
,
Lee I
,
Choi HS
,
Li XY
,
Kang SE
,
Cha SY
,
Ryu JK
,
Na JM
,
Park C
,
Kim K
,
Lee S
,
Gumbiner BM
,
Yook JI
,
Weiss SJ
.
???displayArticle.abstract???
Although loss of p53 function and activation of canonical Wnt signaling cascades are frequently coupled in cancer, the links between these two pathways remain unclear. We report that p53 transactivated microRNA-34 (miR-34), which consequently suppressed the transcriptional activity of β-catenin-T cell factor and lymphoid enhancer factor (TCF/LEF) complexes by targeting the untranslated regions (UTRs) of a set of conserved targets in a network of genes encoding elements of the Wnt pathway. Loss of p53 function increased canonical Wnt signaling by alleviating miR-34-specific interactions with target UTRs, and miR-34 depletion relieved p53-mediated Wnt repression. Gene expression signatures reflecting the status of β-catenin-TCF/LEF transcriptional activity in breast cancer and pediatric neuroblastoma patients were correlated with p53 and miR-34 functional status. Loss of p53 or miR-34 contributed to neoplastic progression by triggering the Wnt-dependent, tissue-invasive activity of colorectal cancer cells. Further, during development, miR-34 interactions with the β-catenin UTR affected Xenopus body axis polarity and the expression of Wnt-dependent patterning genes. These data provide insight into the mechanisms by which a p53-miR-34 network restrains canonical Wnt signaling cascades in developing organisms and human cancer.
???displayArticle.pubmedLink???
22045851
???displayArticle.pmcLink???PMC3447368 ???displayArticle.link???Sci Signal ???displayArticle.grants???[+]
Attiyeh,
Chromosome 1p and 11q deletions and outcome in neuroblastoma.
2005, Pubmed
Attiyeh,
Chromosome 1p and 11q deletions and outcome in neuroblastoma.
2005,
Pubmed
Bale,
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p.
1989,
Pubmed
Bartel,
MicroRNAs: genomics, biogenesis, mechanism, and function.
2004,
Pubmed
Bessard,
Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein.
1998,
Pubmed
,
Xenbase
Bommer,
p53-mediated activation of miRNA34 candidate tumor-suppressor genes.
2007,
Pubmed
Brummelkamp,
A system for stable expression of short interfering RNAs in mammalian cells.
2002,
Pubmed
Burk,
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.
2008,
Pubmed
Calin,
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.
2004,
Pubmed
Chang,
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.
2007,
Pubmed
Chang,
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.
2011,
Pubmed
Cicalese,
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.
2009,
Pubmed
Donehower,
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.
1995,
Pubmed
Donehower,
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
1992,
Pubmed
Donehower,
20 years studying p53 functions in genetically engineered mice.
2009,
Pubmed
Eliyahu,
Wild-type p53 can inhibit oncogene-mediated focus formation.
1989,
Pubmed
Fearon,
A genetic model for colorectal tumorigenesis.
1990,
Pubmed
Finlay,
The p53 proto-oncogene can act as a suppressor of transformation.
1989,
Pubmed
Flynt,
Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate.
2007,
Pubmed
Funayama,
Embryonic axis induction by the armadillo repeat domain of beta-catenin: evidence for intracellular signaling.
1995,
Pubmed
,
Xenbase
Gregory,
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
2008,
Pubmed
Grigoryan,
Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice.
2008,
Pubmed
Gunther,
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.
2003,
Pubmed
Hashimi,
MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation.
2009,
Pubmed
He,
Identification of c-MYC as a target of the APC pathway.
1998,
Pubmed
He,
A microRNA component of the p53 tumour suppressor network.
2007,
Pubmed
Jernigan,
Gbetagamma activates GSK3 to promote LRP6-mediated beta-catenin transcriptional activity.
2010,
Pubmed
,
Xenbase
Ji,
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells.
2009,
Pubmed
Jones,
Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis.
1997,
Pubmed
Kennell,
The microRNA miR-8 is a conserved negative regulator of Wnt signaling.
2008,
Pubmed
Kim,
The effects of wild type p53 tumor suppressor gene expression on the normal human cervical epithelial cells or human epidermal keratinocytes transformed with human papillomavirus type 16 DNA.
1995,
Pubmed
Kim,
MicroRNA biogenesis: coordinated cropping and dicing.
2005,
Pubmed
Kim,
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition.
2011,
Pubmed
Knudson,
Mutation and cancer: statistical study of retinoblastoma.
1971,
Pubmed
Kumar,
Impaired microRNA processing enhances cellular transformation and tumorigenesis.
2007,
Pubmed
Łastowska,
Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
2007,
Pubmed
Lee,
New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites.
2009,
Pubmed
Lee,
MicroRNAs in cancer.
2009,
Pubmed
Levine,
The P53 pathway: what questions remain to be explored?
2006,
Pubmed
Lodygin,
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.
2008,
Pubmed
Logan,
The Wnt signaling pathway in development and disease.
2004,
Pubmed
Martello,
MicroRNA control of Nodal signalling.
2007,
Pubmed
,
Xenbase
Mayr,
Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells.
2009,
Pubmed
Miller,
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
2005,
Pubmed
Molchadsky,
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.
2008,
Pubmed
Morin,
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.
1997,
Pubmed
Nelson,
Convergence of Wnt, beta-catenin, and cadherin pathways.
2004,
Pubmed
Nguyen,
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
2009,
Pubmed
Olivier,
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
2003,
Pubmed
Ota,
Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1.
2009,
Pubmed
Petersen,
Wnt signaling and the polarity of the primary body axis.
2009,
Pubmed
Petitjean,
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
2007,
Pubmed
Riley,
Transcriptional control of human p53-regulated genes.
2008,
Pubmed
Saydam,
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.
2009,
Pubmed
Schwab,
Genomic instability in 1p and human malignancies.
1996,
Pubmed
Tanaka,
Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region.
1993,
Pubmed
Thatcher,
Regulation of zebrafish fin regeneration by microRNAs.
2008,
Pubmed
Thiele,
AU-rich elements and alternative splicing in the beta-catenin 3'UTR can influence the human beta-catenin mRNA stability.
2006,
Pubmed
Thon,
Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.
2009,
Pubmed
Toyota,
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.
2008,
Pubmed
van de Wetering,
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.
2002,
Pubmed
Wan,
LRP6 mediates cAMP generation by G protein-coupled receptors through regulating the membrane targeting of Gα(s).
2011,
Pubmed
Watanabe,
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
2002,
Pubmed
Wei,
The MYCN oncogene is a direct target of miR-34a.
2008,
Pubmed
Wei,
A global map of p53 transcription-factor binding sites in the human genome.
2006,
Pubmed
Welch,
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.
2007,
Pubmed
Xu,
MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells.
2009,
Pubmed
Yamakuchi,
miR-34a repression of SIRT1 regulates apoptosis.
2008,
Pubmed
Yook,
Wnt-dependent regulation of the E-cadherin repressor snail.
2005,
Pubmed
,
Xenbase
Yook,
A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells.
2006,
Pubmed
